Augurex expands its 14-3-3eta test availability through a new partnership with Sonic Reference Laboratory, a division of Sonic Healthcare USA, to enhance the diagnosis and management of rheumatoid arthritis.
Augurex Life Sciences Corp., a leader in the development of autoimmune-based diagnostics, announced the upcoming launch of the 14-3-3eta test, approved as JOINTstat in Canada and the UK, through Sonic Reference Laboratory, a division of Sonic Healthcare USA. Beginning December 15, 2025, the test will be available to healthcare providers across the United States as part of Sonic’s diagnostic portfolio. The 14-3-3eta test improves early detection and management of rheumatoid arthritis (RA), providing clinicians with a powerful tool to enhance care and optimize outcomes.
“Sonic’s national presence and commitment to diagnostic excellence, coupled with their deep global experience in laboratory sciences, makes them an ideal partner to support our mission of improving outcomes for patients with autoimmune diseases.”
14-3-3eta is a clinically proven and validated diagnostic, prognostic and monitoring blood-based biomarker for RA, with elevated levels associated with disease onset, disease severity, progression and an increased risk of joint damage. 14-3-3eta is particularly valuable for identifying patients who may benefit from early intervention, and for patients with seronegative RA. Its role in both diagnosis and ongoing monitoring makes it a powerful tool for informing therapeutic decisions and optimizing long-term outcomes in patients with RA.
“Launching 14-3-3eta with Sonic Reference Laboratory and Sonic Healthcare USA is an important step in broadening access to this important test for clinicians and patients across the U.S.,” said Neil Klompas, CEO of Augurex. “Sonic’s national presence and commitment to diagnostic excellence, coupled with their deep global experience in laboratory sciences, makes them an ideal partner to support our mission of improving outcomes for patients with autoimmune diseases.”
The addition of Sonic Reference Laboratory builds on recent 14-3-3eta test rollouts by other leading laboratories, underscoring the growing momentum for biomarker-based diagnostics in RA. Sonic Healthcare USA, a subsidiary of Sonic Healthcare Limited, is part of one of the world’s largest medical diagnostic companies, delivering laboratory services across eight countries and serving more than 100 million patients annually. Its focus on innovation and quality aligns with Augurex’s commitment to advancing clinical tools that improve patient care in North America and around the world.
Health Technology Insights: Duncan Regional First in U.S. with BD Alaris-MEDITECH EMR Integration
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
